
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics has shown significant revenue growth, with management projecting over 100% revenue growth for the Integrity product line in 2025 compared to 2024, indicating robust demand and market acceptance. Additionally, the company's osteoarthritis pain management revenue outside the U.S. grew by 13% in the first quarter, demonstrating the strength of its international operations. Furthermore, the regenerative solutions segment reported an impressive 41% growth driven by the Integrity patch, highlighting the potential of its innovative product offerings in the orthopedic market.
Bears say
Anika Therapeutics reported revenue of $28.2 million, reflecting an 8.2% decline compared to the same period last year, indicating a troubling trend in performance. Additionally, the company's international osteoarthritis (OA) pain revenue decreased by 10%, exacerbated by order timing and production yield issues, suggesting operational challenges. The ongoing negative news flow over the past 12-18 months further reinforces the company's precarious financial position, contributing to a generally negative outlook for its stock.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares